| SciPort RLP

2023 - 2024

Improving cancer immunotherapy by neutrophil granulocyte-mediated T cell hyperactivation

Dr. Stephanie Reichert

2023

The extent of health-related information in patients with malignant lymphoma: Development of a multimodal education concept

Dr. Stephanie Herold

2023 - 2024

Investigation on the cross talk between NK cells and T cells in cellular Immunotherapies

Dr. Jonas Wißkirchen

2023 - 2027

MATAO

Univ.-Prof. Dr. Annette Hasenburg,
Dr. Katrin Almstedt,
PD Dr. Marco Battista

2023 - 2026

Rassistische Diskriminierung im Kontext psychischer Gesundheitsversorgung (RaDiGe)

Dr. Nora Hettich-Damm

2023 - 2030

Viktoria 1

Univ.-Prof. Dr. Marcus Schmidt,
Dr. Slavomir Krajnak

2023 - 2030

eVERA

Univ.-Prof. Dr. Marcus Schmidt,
Dr. Slavomir Krajnak

2023 - 2040

An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas (DAREON™-5) (#1472)

Dr. Jürgen Alt

2023 - 2040

A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation (SNDX-5613-0700) (#1456)

Univ.-Prof. Dr. Michael Kühn

2023 - 2025

Schlafeinleitung durch Lachgas/Sauerstoff-Gasmischung (SELAS)

Prof. Dr. Haralampos Gouveris

Klinikum

FB 04 - Universitätsmedizin / Johannes Gutenberg-Universität Mainz

Starten Sie Ihre Suche...

Klinikum

FB 04 - Universitätsmedizin / Johannes Gutenberg-Universität Mainz